Q1 2025 Earnings Forecast for Apellis Pharmaceuticals, Inc. Issued By Zacks Research (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at Zacks Research dropped their Q1 2025 EPS estimates for shares of Apellis Pharmaceuticals in a report released on Tuesday, April 23rd. Zacks Research analyst R. Department now expects that the company will post earnings of ($0.01) per share for the quarter, down from their prior estimate of $0.06. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q3 2025 earnings at $0.39 EPS and FY2025 earnings at $1.05 EPS.

A number of other analysts also recently commented on APLS. Raymond James boosted their target price on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a report on Thursday, January 11th. Robert W. Baird reiterated an “outperform” rating and issued a $81.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, February 6th. The Goldman Sachs Group boosted their target price on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, January 9th. Needham & Company LLC restated a “buy” rating and set a $85.00 price target on shares of Apellis Pharmaceuticals in a report on Thursday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Stock Up 4.0 %

NASDAQ APLS opened at $49.86 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. The company’s 50 day simple moving average is $58.21 and its 200 day simple moving average is $57.30. Apellis Pharmaceuticals has a 12 month low of $19.83 and a 12 month high of $94.75. The company has a market capitalization of $6.01 billion, a P/E ratio of -11.31 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, hitting analysts’ consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. During the same period in the previous year, the firm earned ($1.50) EPS. Apellis Pharmaceuticals’s revenue was up 545.9% on a year-over-year basis.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of APLS. Jennison Associates LLC lifted its stake in shares of Apellis Pharmaceuticals by 79.8% in the third quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock worth $134,746,000 after buying an additional 1,571,606 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Apellis Pharmaceuticals by 109.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after buying an additional 1,121,497 shares during the last quarter. Norges Bank acquired a new stake in shares of Apellis Pharmaceuticals in the fourth quarter worth $56,640,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Apellis Pharmaceuticals by 38.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock worth $147,277,000 after buying an additional 677,098 shares during the last quarter. Finally, Polar Capital Holdings Plc raised its stake in Apellis Pharmaceuticals by 126.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after purchasing an additional 588,875 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Jeffrey Delong sold 9,913 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $56.90, for a total transaction of $564,049.70. Following the completion of the sale, the insider now owns 54,693 shares of the company’s stock, valued at $3,112,031.70. The disclosure for this sale can be found here. Insiders sold 381,011 shares of company stock valued at $23,463,657 over the last ninety days. Corporate insiders own 7.50% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).